Skip to main content

Table 2 Characterisation of EVs in saliva and tear fluid

From: Identification of potential saliva and tear biomarkers in primary Sjögren’s syndrome, utilising the extraction of extracellular vesicles and proteomics analysis

  Mean particle sizea(nm) Particles/mla CD9+ EVs S/N ratio MFIb
Saliva
 Patients with pSS 189 ± 4.1 5.46 E + 10 ± 1.43 E + 10* 3.47 ± 0.56*
 Controls 189 ± 4.4 2.41 E + 10 ± 3.98 E + 09 1.93 ± 0.15
Tear fluid
 Patients with pSS 171 ± 6.9 1.54 E + 09 ± 3.08 E + 08 1.10 ± 0.03
 Controls 163 ± 9.6 1.09 E + 09 ± 1.06 E + 08 1.06 ± 0.02
 Pool of patients with pSS 190 2.04 E + 10 2.88
 Pool of controls 144 8.45 E + 09 1.06
  1. aNanoparticle tracking analysis was conducted on extracellular vesicles (EV) joint fractions from whole saliva (n = 19 patients with primary Sjögren’s syndrome (pSS), n = 32 controls), tear fluid (n = 7 patients with pSS, n = 6 controls), and one pooled tear sample (n = 11 patients with pSS, n = 5 controls) to determine mean particle size of microvesicles and exosomes (nm ± SEM), in addition to concentrations of EVs (particles/ml ± SEM).bDetection of CD9+ EVs from joint fractions of saliva (n = 19 patients with pSS, n = 32 controls), tear fluid (n = 11 patients with pSS, n = 10 controls), and one pooled tear sample (n = 11 patients with pSS, n = 5 controls) was performed by immunoaffinity capture using anti-CD9-coated magnetic beads followed by flow cytometry analysis. The results were reported as signal-to-noise (S/N) ratios of median fluorescence intensity (MFI). *Significant difference between patients with pSS and controls (unpaired t test, p < 0.05)